Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MST-188 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Study Drug | EXPERIMENTAL | MST-188 |
| MST-188 | EXPERIMENTAL | MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours. |
| Saline | PLACEBO_COMPARATOR | Saline administered as a continuous infusion for up to 49 hours |
| Name | Type | Description |
|---|---|---|
| MST-188 | DRUG | Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours. |
| Saline | DRUG | - |
Inclusion Criteria: * Completed participation in study MST-188-01 (EPIC study) * Subject age 4 through 65 years * Subject is experiencing acute pain typical of VOC and requires treatment with parenteral opioid analgesia * Subject requires hospitalization Exclusion Criteria: * Subject has acute ch...
Top 11 of 12 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Etavopivat |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE3 | Crizanlizumab, OTQ923, ITU512 |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE3 | PCV21, rilzabrutinib |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | CTX001 |
| Agios Pharmaceuticals, Inc. | AGIO | 2 | PHASE2 | Mitapivat, Tebapivat |
| Pfizer Inc. | PFE | 1 | PHASE2 | Osivelotor |
| Bristol-Myers Squibb Company | BMY | 1 | PHASE1 | BMS-986470 |
| Fulcrum Therapeutics, Inc. | FULC | 1 | PHASE2 | Pociredir |
| Beam Therapeutics, Inc. | BEAM | 2 | PHASE1 | BEAM-101 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-3405 |
| Editas Medicine, Inc. | EDIT | 2 | PHASE1 | EDIT-301 |
MST-188 is an investigational small molecule being developed for vaso-occlusive crisis in sickle cell disease. It is designed to address the acute painful episodes caused by blocked blood flow. MST-188 is currently in clinical development and has not been approved by the FDA.
MST-188 is being developed by Savara, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker SVRA. Savara is conducting clinical trials to evaluate the safety and efficacy of MST-188 for the treatment of vaso-occlusive crisis in sickle cell disease.
MST-188 is in Phase 3 clinical development. Two Phase 3 trials have been completed, including a large study with 388 participants and a smaller repeat-administration study with 16 participants. MST-188 remains investigational and is not yet approved for any use.
MST-188 has been studied in two completed Phase 3 trials. The primary trial, NCT01737814, enrolled 388 participants with vaso-occlusive crisis of sickle cell disease across multiple countries. A second trial, NCT02449616, evaluated repeat administration in 16 participants with sickle cell disease in the United States.
MST-188 is a purified poloxamer 188, a small molecule that targets vaso-occlusive crisis in sickle cell disease. It is designed to improve blood flow by reducing the adhesion of sickled red blood cells to blood vessel walls, thereby helping to prevent and resolve the blockages that cause painful crises.